Sotabase

Career

· Senior Web Engineer, TigerConnect2018–
· Software Engineer, ID TECH2016–2018
· Web Application Developer Intern, The Portal2016–2016
· Front End Web Developer Intern, Orbee2015–2016

Publications (127)

Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial
Journal of the American Medical Association (JAMA) · 2017
2,050
cited
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial.
Journal of the American Medical Association (JAMA) · 2015
1,148
cited
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.
The Lancet Oncology · 2017
869
cited
First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma
Journal of Translational Medicine · 2018
474
cited
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma
JAMA Oncology · 2022
313
cited
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma
2017
302
cited
Central nervous system cancers.
The Journal of the National Comprehensive Cancer Network · 2005
269
cited
Hyperthermic Laser Ablation of Recurrent Glioblastoma Leads to Temporary Disruption of the Peritumoral Blood Brain Barrier
PLoS ONE · 2016
188
cited
Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial
Clinical Cancer Research · 2020
132
cited
An NAD+-dependent transcriptional program governs self-renewal and radiation resistance in glioblastoma
Proceedings of the National Academy of Sciences of the United States of America · 2016
119
cited
Central Nervous System Cancers, Version 1.2015.
The Journal of the National Comprehensive Cancer Network · 2015
108
cited
Stereotactic laser ablation of high-grade gliomas.
Neurosurgical Focus · 2014
106
cited
A CDC20-APC/SOX2 Signaling Axis Regulates Human Glioblastoma Stem-like Cells.
Cell Reports · 2015
103
cited
Characterization and management of dermatologic adverse events with the NovoTTF-100A System, a novel anti-mitotic electric field device for the treatment of recurrent glioblastoma.
Seminars in Oncology · 2014
99
cited
Clinical and Dosimetric Predictors of Acute Severe Lymphopenia During Radiation Therapy and Concurrent Temozolomide for High-Grade Glioma.
International Journal of Radiation Oncology, Biology, Physics · 2015
91
cited
107 ReACT: Overall Survival From a Randomized Phase II Study of Rindopepimut (CDX-110) Plus Bevacizumab in Relapsed Glioblastoma
2015
86
cited
Tumor Treating Fields in the Management of Patients with Malignant Gliomas
Current Treatment Options in Oncology · 2020
83
cited
Central nervous system cancers, version 2.2014. Featured updates to the NCCN Guidelines.
The Journal of the National Comprehensive Cancer Network · 2014
81
cited
A phase I study to repurpose disulfiram in combination with temozolomide to treat newly diagnosed glioblastoma after chemoradiotherapy
Journal of Neuro-Oncology · 2016
69
cited
A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE)
Neuro-Oncology · 2019
66
cited
Sotabase